These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 32321830)
1. Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. Esswein SR; Gristick HB; Jurado A; Peace A; Keeffe JR; Lee YE; Voll AV; Saeed M; Nussenzweig MC; Rice CM; Robbiani DF; MacDonald MR; Bjorkman PJ Proc Natl Acad Sci U S A; 2020 May; 117(18):9865-9875. PubMed ID: 32321830 [TBL] [Abstract][Full Text] [Related]
2. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880 [TBL] [Abstract][Full Text] [Related]
3. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731 [TBL] [Abstract][Full Text] [Related]
4. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies. Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS mBio; 2019 Sep; 10(5):. PubMed ID: 31530669 [TBL] [Abstract][Full Text] [Related]
5. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857 [TBL] [Abstract][Full Text] [Related]
6. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Wu Y; Li S; Du L; Wang C; Zou P; Hong B; Yuan M; Ren X; Tai W; Kong Y; Zhou C; Lu L; Zhou X; Jiang S; Ying T Emerg Microbes Infect; 2017 Oct; 6(10):e89. PubMed ID: 29018252 [TBL] [Abstract][Full Text] [Related]
7. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model. Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774 [TBL] [Abstract][Full Text] [Related]
8. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A J Virol; 2020 May; 94(10):. PubMed ID: 32132233 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. Zhao H; Xu L; Bombardi R; Nargi R; Deng Z; Errico JM; Nelson CA; Dowd KA; Pierson TC; Crowe JE; Diamond MS; Fremont DH J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757867 [TBL] [Abstract][Full Text] [Related]
11. A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies. Graham SD; Tu HA; McElvany BD; Graham NR; Grinyo A; Davidson E; Doranz BJ; Diehl SA; de Silva AM; Markmann AJ J Virol; 2021 Apr; 95(9):. PubMed ID: 33597214 [TBL] [Abstract][Full Text] [Related]
12. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259 [TBL] [Abstract][Full Text] [Related]
13. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206 [TBL] [Abstract][Full Text] [Related]
14. He Y; Zhong L; Yan H; Virata ML; Deng L; Mishra AK; Struble E; Scott D; Zhang P Microbiol Spectr; 2024 Jun; 12(6):e0075824. PubMed ID: 38687079 [TBL] [Abstract][Full Text] [Related]
16. A Novel Neutralizing Antibody Targeting a Unique Cross-Reactive Epitope on the hi Loop of Domain II of the Envelope Protein Protects Mice against Duck Tembusu Virus. Chen X; Li C; Lin W; Li T; Li X; Bai X; Wulin S; Zhang Q; Li S; Liu M; Liu JH; Zhang Y J Immunol; 2020 Apr; 204(7):1836-1848. PubMed ID: 32132180 [TBL] [Abstract][Full Text] [Related]
17. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS mBio; 2016 Jul; 7(4):. PubMed ID: 27435464 [TBL] [Abstract][Full Text] [Related]
18. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge. De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection. Garg H; Yeh R; Watts DM; Mehmetoglu-Gurbuz T; Resendes R; Parsons B; Gonzales F; Joshi A BMC Immunol; 2021 Jan; 22(1):5. PubMed ID: 33421988 [TBL] [Abstract][Full Text] [Related]